Sugi Predict

Sugi Predict / Compounds / SCHEMBL24745112

SCHEMBL24745112

SCHEMBL24745112

Cc1nn(C)c(C)c1-c1c(Cl)ccc2c(CCCOc3cccc4cc(F)ccc34)c(C(=O)OC(C)(C)C)[nH]c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 17/20 0.55
▸ EEF2K O00418 1/20 0.55
▸ MARK3 P27448 1/20 0.55
▸ AXL P30530 1/20 0.55
▸ BCL6 P41182 1/20 0.55
▸ NEK4 P51957 1/20 0.55
▸ PRKCD Q05655 1/20 0.55
▸ PRKAA1 Q13131 1/20 0.55
▸ CAMK2B Q13554 1/20 0.55
▸ CAMK2G Q13555 1/20 0.55
▸ CAMK2D Q13557 1/20 0.55
▸ MARK2 Q7KZI7 1/20 0.55
▸ PIM3 Q86V86 1/20 0.55
▸ HIPK2 Q9H2X6 1/20 0.55
▸ MKNK2 Q9HBH9 1/20 0.55
▸ MAP3K20 Q9NYL2 1/20 0.55
▸ MAP4K5 Q9Y4K4 1/20 0.55
▸ BCL2L1 Q07817 7/20 0.51
▸ BCL2 P10415 4/20 0.51
▸ BAD Q92934 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30000890 1.00 MCL1 (0.55) MCL1EEF2KMARK3AXLBCL6
SCHEMBL24745588 0.95 MCL1 (0.54) MCL1EEF2KMARK3AXLBCL6
SCHEMBL31090520 0.95 MCL1 (0.54) MCL1EEF2KMARK3AXLBCL6
SCHEMBL30000896 0.93 MCL1 (0.56) MCL1EEF2KMARK3AXLBCL6
SCHEMBL24745163 0.93 MCL1 (0.56) MCL1EEF2KMARK3AXLBCL6
SCHEMBL24744627 0.93 MCL1 (0.64) MCL1EEF2KMARK3AXLBCL6
SCHEMBL30000684 0.93 MCL1 (0.64) MCL1EEF2KMARK3AXLBCL6
SCHEMBL24745108 0.91 MCL1 (0.56) MCL1EEF2KMARK3AXLBCL6
SCHEMBL30000272 0.91 MCL1 (0.56) MCL1EEF2KMARK3AXLBCL6
SCHEMBL24745109 0.90 MCL1 (0.67) MCL1EEF2KMARK3AXLBCL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 — — US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 — — CN disclosed
WO-2022255888-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 — — WO disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP MCL1 1/4885EEF2K 2059/4885MARK3 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.